These findings not only support the oncogenic role of specific ChREBP isoforms in the HCC pathogenesis [21] but also provide evidence that the hepatic ChREBP deletion, while leaving tumor initiation unaffected, markedly reduces the tumor progression. This evidence concerns the gene MLXIPL and hepatocellular carcinoma.